Search results
Results from the WOW.Com Content Network
Meanwhile, a trial of Wegovy, the version of Ozempic approved for weight loss, showed adults without diabetes who took the drug lost an average of 12.4% of their initial body weight after a year ...
Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from ...
While both medications showed a significant weight loss benefit, after 72 weeks on treatment, people treated with Zepbound lost 20% of their body weight, compared to people on Wegovy who lost just ...
They also reported that 31% of people taking Zepbound achieved at least 25% body weight loss compared to 16% for those taking Wegovy. On average, people taking Zepbound lost about 50 pounds, while ...
People taking Zepbound were also more likely to reach specific weight loss targets than those taking Wegovy: About 32% of those taking Zepbound lost at least 25% of their body weight, compared ...
The researchers looked at how much weight the patients lost after 3, 6 and 12 months. People who took semaglutide lost, on average, 3.6% of their body weight after 3 months; 5.8% after 6 months ...
In a press release, Lilly announced that in its latest trial comparing its medication, Zepbound, to Wegovy, made by Novo Nordisk, people randomly assigned to receive Zepbound lost about 20% of ...
Bansal compares weight-loss results from Zepbound to that of bariatric surgery, which can lead to weight loss of 10% to 15% of a patient's body weight, and surgical procedures like gastric sleeve ...